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Quinidine elevates serum digoxin concentration in part
by reducing the volume of distribution of digoxin, which
implies that quinidine displaces digoxin from tissues.
The purposes of this study were to: 1) measure the effect
of quinidine on tissue digoxin concentrations, and 2) de-
termine if quinidine alters the relation between myo-
cardial digoxin concentration and digoxin effecton myo-
cardial monovalent cation transport.
Eighteen dogs were treated with tritiated digoxin un-
til the steady-state serum digoxin concentration was be-
tween 1.0 and 1.5 ng/ml. All dogs continued receiving
the same dose of digoxin while nine dogs were given
quinidine as well.Quinidine wascontinued until the serum
digoxin concentration had increased by at least 25%. At
the end of treatment, the serum digoxin concentration
When quinidine is given to patients receiving digoxin, the
serum digoxin concentation irtcreases because of a reduction
in digoxin volume of distribution as well as decreases in
digoxin renal and total body clearances (1-3). The observed
reduction of digoxin volume of distribution during quinidine
treatment implies that quinidine interferes with digoxin tis-
sue binding (1-3). Studies in patients (4,5) and intact animal
models (6,7) of the quinidine-digoxin interaction have failed
to identify the tissues responsible for the reduction in digoxin
volume of distribution seen during quinidine administration.
Although it appeared from early studies in patients by Schenck-
Gustafsson et al. (4) that quinidine displaced digoxin from
binding sites in skeletal muscle, a more recent study (5)
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in dogs treated with digoxin was 1.2 ± 0.1 nglml com-
pared with 2.1 ± 0.5 nglml in dogs treated with digoxin
and quinidine in combination (p < 0.001). Digoxin con-
centration in myocardium, skeletal muscle, liver, kid-
ney, stellate ganglion, vagus nerve, femoral nerve, brain
and brainstem medulla was higher in dogs treated with
a combination of digoxin and quinidine than in dogs
treated with digoxin alone, but remained proportional
to the serum digoxin concentration in all tissues except
the brainstem medulla. Myocardial monovalent cation
transport was measured using rubidium-86. The effect
of digoxin on myocardial monovalent cation transport
did not increase as the serum and myocardial digoxin
concentrations increased after quinidine administration.
(J Am Coli CardioI1985;5:680-6)
from the same laboratory did not confirm the earlier finding.
Animal models of the quinidine-digoxin interaction have
been used to measure digoxin concentrations in a variety of
tissues (6,7). These previous studies of steady-state tissue
digoxin concentration in intact animals yielded conflicting
results and were flawed by the failure to produce an increase
in serum digoxin concentration in animals treated with quin-
idine (6,7).
The relation between the serum digoxin concentration
and the effect of digoxin during the quinidine-digoxin in-
teraction is not clear. If digoxin was displaced from active
binding sites in the myocardium by quinidine, the effect of
digoxin might not increase as the serum digoxin concentra-
tion increases during quinidine administration. Studies (8-12)
in patients using low doses of digoxin and quinidine and
insensitive methods of measuring digoxin effect have been
inconclusive. Warner (13) and Somberg (14) and their co-
workers found that myocardial monovalent cation transport
is not reduced as much as expected from the serum digoxin
concentration after quinidine administration to intact dogs.
Goldman et al. (15) measured the effect of cardiac glyco-
sides on myocardial contractility during quinidine admin-
stration in conscious dogs and found that quinidine atten-
uated the inotropic effect of ouabain. A reduction in the
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ratio of the myocardial/serum digoxin concentration could
explain the findings of these studies (13-15) .
The purposes of our study were to: I) measure tissue
digoxin concentrations during the quinidine-digoxin inter-
action, and simultaneously 2) compare the myocardial di-
goxin concentration with the effect of digoxin on electro-
cardiographic intervals and myocardial monovalent cation
transport during quinidine administration. A dose-ranging
method of digoxin administration was used to ensure an
increase in the serumdigoxinconcentration duringquinidine
dosing. All measurements were made after the digoxin con-
centration had increased to a new steady-state level during
quinidine administration.
Methods
Experimental preparation. We useddose-ranging with
digoxin and quinidine to produce a substantial quinidine-
digoxin interaction and to minimize between-dog variability
in serum digoxin concentration within each experimental
group (13). Digoxin specifically labeled at the 12-alpha
position with 0.2 j.LCi of tritium per j.Lg of digoxin (New
England NuclearCorp.) was given to 18male mongrel dogs
(weighing II to 21 kg) until a steady-state serum digoxin
concentration of 1.0 to 1.5 ng/ml wasobtained. The average
digoxin dose was 10.4 ± 1.6 j.Lg/kg per day. When the
steady-state serum digoxin concentration was 1.0 to 1.5
ng/ml, dogs were anesthetized with 30 mg/kg of pentobar-
bital for placement of internal jugular catheters and biopsy
of the sternocleidomastoid muscle. After catheter place-
ment, all dogs continued to receive the same dose of di-
goxin. Nine of the dogs also received quinidine sulfate, 12
mg/kg intravenously through the internal jugular catheter
every 6 hours, and the remainingnine dogs receivednormal
saline solution. Quinidine was continued until serum di-
goxin concentration increased at least 25% (4 to 7 days,
mean 5.5). Rubidium uptake and tissue digoxin concentra-
tions were measured 18 to 24 hours after the last dose of
digoxin and 3 to 6 hours after the last dose of quinidine was
administered.
Measurement of serum digoxin and quinidine con-
centrations. Serum digoxin concentration was measured
by counting tritium in duplicate 500 j.Ll samples and com-
pared the counts per minute to the counts per minute from
a known amount of tritiated digoxin. An internal standard
was used to allow correctionfor quenching (7). Serumquin-
idine concentration was measured by high pressure liquid
chromatography afterextracting plasma samples by themethod
of Cramer and Isaakson (16).
Determination of rubidium-86 uptake. Our methodof
measurement of myocardial monovalent cation transport us-
ing rubidium-86 has recently been described (13). Briefly,
samples of left ventricularmyocardium were obtained from
anesthetized ventilated dogs and incubated in physiologic
buffer containing rubidium-86 with or without 10- 3 M of
ouabain. After a 30 minute incubation, samples were rinsed
and Cerenkovradiation was counted. Total rubidiumuptake
expressed as nmol rubidium/mg tissue per 30 minutes was
calculated by comparing the counts per minute from stan-
dards to the counts per minute from the tissue sections.
Passive ribidium uptake was calculated from the counts per
minute of tissue sections incubated in buffer containing
10 - 3 M of ouabain. Active rubidium uptake was calculated
by subtracting passive from total rubidium uptake.
Measurement of electrocardiographic intervals.
Electrocardiographic leads I and II were recorded on an
Electronics for Medicine VR12 recorder at a paper speed
of 100 mm/s. The RR, PR, QRS and QT intervals were
measured from these recordings; QTc was calculated using
the formula QT/RR'I2.
Measurement of tissue digoxin concentration. Three
50 mgsamplesof myocardium,twoseparateskeletalmuscles
(sternocleidomastoid and quadriceps femoris) , kidney cor-
tex, kidney medulla, liver, cerebral cortex (gray matter),
cerebralwhitematter, cerebellum, hypothalamus,pons, me-
dulla, femoral nerve, vagus nerveand stellateganglionwere
obtained. Tissue samples were blotted dry on bibulous pa-
per, weighedand dissolvedby overnight incubation at 45° C
in 0.5 ml of Protosol (New England Nuclear Corp.) Gla-
cial acetic acid (0.02 rnl) was added to each sample to make
it less alkaline. After the addition of scintillation medium
(Biofluor, New England Nuclear Corp.), samples were
counted in a liquid scintillation counter until there was no
difference betweenone set of counts and the next, indicating
that there was no remaining chemiluminescence. To permit
correction for quenching, an internal standard containing
approximately 5,000 counts/min of tritiated digoxin was
added to each sample and the samples were again counted
until there was no difference in serial counts per minute.
By comparison with the counts per minute obtained from a
knownconcentration of tritiated digoxin, the tissue digoxin
concentration was calculated in ng/g wet tissue weight. The
average digoxin concentration of the three samples from
each tissue was calculated for each dog and used in the
statistical analysis.
Statistical analysis. The ratio of tissue to serumdigoxin
concentration was calculatedby dividing tissuedigoxincon-
centration by serumdigoxinconcentration. Meanvaluesand
standard deviations of serum and tissue digoxin concentra-
tions and of the tissue to serum digoxin concentration ratios
were calculated for each tissue in both groups of dogs.
Student's t test for group mean values was used to compare
the serum digoxin concentration, tissue digoxin concentra-
tion, rubidium uptake and electrocardiographic intervals of
the two treatment groups. Paired t tests were used to: I)
compare the serum digoxin concentration before and after
treatment with quinidine or saline solution; and 2) compare
the concentration of digoxin in the sternocleidomastoid mus-
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Results
Figure 1. Serum digoxinconcentration at the end of the study for
each dog treated with digoxin and serum digoxin concentrations
immediately before quinidine treatment (PRE-Q) and at the end
of the study (POST-Q) for each dog treated with digoxin and
quinidine in combination. Eight of the nine dogs treated with
digoxin and quinidine had an increase in serum digoxin concen-
trationduringquinidine treatment. Thedog in whichserumdigoxin
concentration did not increase during quinidine treatment was not
included in the study.
c1e and the ratio of sternocleidomastoid muscle to serum
digoxin concentration before and after quinidine or saline
solution treatment in each group of dogs. Regression anal-
ysis was used to quantitate the relation between the serum
digoxin concentration and the RR, PR, QRS, QT and QTc
intervals, the myocardial digoxin concentration and the RR,
PR, QRS, QT and QTc intervals and the serum quinidine
concentration and the RR, PR, QRS, QT and QTc intervals.
18A ± 5At
15, I ± 3.7t
50.3 ± 29,Ot
16.9 ± 12.1
21.5 ± 6.1t
23.9 ± 10.8*
20,3 ± 11.1
31.0 ± 8,0*
19.7 ± 2.9
2, I ± 0.1t
67.0 ± 19.1t
524,6 ± 184.2t
138.8 ± 60, It
60A ± 20.9t
14,0 ± 4.5t
12.1 ± 3.0t
Digoxin and Quinidine
(n = 8)
Digoxin
(n = 9)
10.9 ± 2.7
8.6 ± 5.2
21A ± 8.7
15,7 ± 3.8
11.7 ± 8A
19.9±IIA
18.0 ± 5.2
11.0 ± 2.5
11.0 ± 5.8
1.2 ± 0.2
41.9 ± 7.9
287.1 ± 65.2
57.8 ± 14.1
34.3 ± 7.8
8.1 ± 3.1
8.6 ± 2.5
Tissue
*p < 0.05; t p < 0.01.
Table I. Tissue Digoxin Concentrations (ng/g)
Serum (ng/m!)
Myocardium
Renal cortex
Renal medulla
Liver
Quadriceps femoris
Sternocleidomastoid
muscle
Cerebral gray
matter
Cerebral white
matter
Cerebellum
Hypothalamus
Pons
Medulla
(brainstem)
Femoral nerve
Vagus nerve
Stellate ganglion
0.001). One dog did not have any evidence of a quinidine-
digoxin interaction (Fig. I). In other words, the serum di-
goxin concentration did not increase after quinidine was
administered to this dog despite a serum quinidine concen-
tration ranging from 3. 16 to 7.44 JLg/ml during 6 days of
quinidine treatment. This dog was excluded from analysis
because it did not meet the study requirement that the serum
digoxin concentration increase by at least 25% after quin-
idine treatment. The remaining eight dogs that received
digoxin and quinidine had an average serum digoxin con-
centration of 1.1 ± 0.1 ng/ml before quinidine treatment.
The average serum digoxin concentration of these eight dogs
increased by 91% to 2.1 ± 0.5 ng/ml after 5.5 days of
quinidine treatment.
Tissue digoxin concentrations. Table I shows the av-
erage digoxin concentration in tissues of dogs treated with
digoxin alone and dogs treated with a combination of di-
goxin and quinidine. Dogs treated with digoxin and quin-
idine had higher tissue digoxin concentrations in all tissues
except four sites in the brain: cerebral white matter, cere-
bellum, hypothalamus and brainstem medulla, Table 2 shows
the ratio of tissue to serum digoxin concentration for dogs
treated with digoxin alone compared with those treated with
digoxin and quinidine in combination. In all tissues except
the brainstem medulla, the ratio between tissue and serum
digoxin concentration was the same in the dogs treated with
digoxin and quinidine as in dogs treated with digoxin alone.
In the brainstem medulla, the concentration of digoxin was
not significantly higher in dogs treated with quinidine, and
the ratio of tissue/serum digoxin concentration was lower
during quinidine treatment (p < 0.01).
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Serum digoxin concentrations before and after quin-
idine administration. Figure I shows the serum digoxin
concentrations of the digoxin-treated dogs after digoxin
treatment and of the digoxin- and quinidine-treated dogs
both before quinidine was begun and after digoxin and quin-
idine treatment. The average serum digoxin concentration
of the nine dogs that did not receive quinidine was 1.4 ±
0.7 ng/ml (mean ± standard deviation) before randomi-
zation and 1.2 ± 0.1 ng/ml at the end of the study. Dogs
that received quinidine had a serum digoxin concentration
of 1.3 ± 0.2 ng/ml before quinidine treatment. After an
average of 5.5 days of treatment with quinidine, the serum
quinidine concentrations ranged from 1.8 to 12.8 JLg/ml
(mean 5.5 ± 3.4). During treatment with quinidine, the
serum digoxin concentration in dogs treated with digoxin
and quinidine increased by 74% to 2.1 ± 0.5 ng/ml (p <
lACC Vol. 5. No.3
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Table 2. Ratio of Tissue/Serum Digoxin Concentration
(ng/g:ng/ml)
Sternocleidomastoid muscle: serum digoxin concen-
tration. The ratio of sternocleidomastoid muscle to serum
digoxin concentration is shown in Figure 2 for each dog
2.1 ± 0.1t
572 ± 189*
109 ± 29
53 ± 9
241 ± 38t
324 ± 19
67.0 ± 19.1t
0.165 ± 0.054
Digoxin and Quinidine
(n = 8)
Digoxin
(n = 9)
1.2 ± 0.2t
396 ± 108*
97 ± 12
49 ± 7
193 ± 14t
312 ± 23
41.9 ± 7.9t
0.157 ± 0.043
*p < (J.()5; tp < 0.01.
Table 3. Rubidium Uptake and Electrocardiographic Intervals
before and after quinidine or saline solution treatment. At
randomization, the digoxin concentration in the sternoclei-
domastoid muscle averaged 7.9 ± 2.8 ng/g in the dogs
given digoxin treatment alone and 7.3 ± 1.9 ng/g in the
dogs given digoxin and quinidine treatment. The ratio of
sternocleidomastoid muscle/serum digoxin concentration was
5.7 ± 1.4 in dogs that received digoxin alone and 6.5 ±
2.1 in dogs that received digoxin and quinidine in combi-
nation. Both the concentration of digoxin in the muscle and
the ratio of muscle to serum digoxin concentration remained
constant when digoxin was continued in the same dose after
a steady-state serum digoxin concentration had been achieved
(Tables I and 2). When quinidine was added to digoxin
treatment, the serum digoxin concentration increased and
the concentration of digoxin in the sternocleidomastoid mus-
cle increased correspondingly (Table I). With quinidine
treatment, the ratio of sternocleidomastoid to serum digoxin
concentration increased slightly in four dogs and decreased
in four dogs (Fig. 2), remaining on the average the same
as before quinidine treatment (Table 2).
Serum and myocardial digoxin concentrations, ru-
bidium uptake and electrocardiographic intervals.
Table 3 shows the serum digoxin concentration, myocardial
digoxin concentration, active myocardial rubidium uptake,
RR, PR, QRS, QT and QTc intervals of dogs in the two
treatment groups. Rubidium uptake for each dog in the study
is shown in Figure 3. The mean rubidium uptake for the
dogs treated with digoxin was 0.157 ± 0.043 nmollmg per
30 minutes. This did not differ from the rubidium uptake
of 0.165 ± 0.054 nmollmg per 30 minutes of the dogs
treated with digoxin and quinidine together. Heart rate var-
ied from dog to dog in both groups of pentobarbital-anes-
thetized dogs. There was, however, a statistically significant
difference in the average RR intervals of the two groups of
dogs. The slower heart rate in dogs treated with quinidine
Serum digoxin
concentration
(ng/ml)
Myocardial digoxin
concentration (ng/g)
Rubidium uptake
(nmol/mg per 30
minutes)
RR (ms)
PR (rns)
QRS (ms)
QT (ms)
QTc (ms)
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Digoxin Digoxin and Quinidine
Tissue (n = 9) (n = 8)
Myocardium 36.2 ± 4.0 32.0 ± 8.5
Renal cortex 252.0 ± 66.0 248.9 ± 80.0
Renal medulla 51.5 ± 18.7 65.1 ± 24.7
Liver 30.0 ± 6.6 27.9 ± 6.7
Quadriceps femoris 7.0 ± 2.1 6.9 ± 2.9
Sternocleidomastoid 7.5 ± 24 5.7 ± 1.1
muscle
Cerebral gray 9.6 ± 5.0 10.3 ± 3.2
matter
Cerebral white 9.6 ± 60 7.9 ± 54
matter
Cerebellum 13.7 ± 33 Il.l ± 3.8
Hypothalamus 10.3 ± 7.8 9.8 ± 5.3
Pons 16.8 ± 8.1 15.8 ± 8.5
Medulla 15.3 ± 2.9 9.8 ± 3.6*
Femoral nerve 9.5 ± 2.1 8.7 ± 2.1
Vagus nerve 74 ± 3.7 7.1 ± 14
Stellate ganglion 18.9 ± 9.1 23.0 ± 10.2
*p < 0.01.
Figure 2. Sternocleidomastoid muscle/serum digoxin concentra-
tion ratio at the time of randomization of dogs to quinidine (right)
or saline solution (left) treatment and at the end of the study.
Paired t tests show no significant differencein sternocleidomastoid
muscle/serum digoxin concentration ratio in either group.
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BP = blood pressure; K = potassium; Na = sodium; P02 = partial
pressure of oxygen; PC02 = partial pressure of carbon dioxide.
Table 4. Serum Electrolyte Concentrations, Arterial Blood
Gases, Systolic and Diastolic Blood Pressures
Discussion
Tissue concentrations of digoxin. Interpretation of in-
tact animal studies of steady-state tissue digoxin concentra-
Figure 3. Active myocardial rubidium uptake for each dog in the
study. Dogs treatedwithdigoxinandquinidine had a higherserum
digoxin concentration (SOC) than did dogs treated with digoxin
alone, but therewas nodifference in activemyocardial monovalent
cation transport between the two groups.
tion during the quinidine-digoxin interaction has been lim-
ited by the failure of these studies to demonstrate an increase
in serum digoxin concentration during quinidine adminis-
tration (6,7). We used a dose-ranging method of drug
administration to produce an increase in serum digoxin con-
centration during quinidine treatment of 91%, from I. I ±
0.1 to 2.1 ± 0.5 ng/ml in eight of nine dogs treated with
digoxin and quinidine in combination (Fig. I). During the
same time period, the serum digoxin concentration in nine
dogs treated with digoxin alone did not change and averaged
1.2 ± 0.1 ng/ml at the end of the study.
We were unable to identify a tissue or tissues responsible
for the reduction in digoxin volume of distribution that has
been reported (1-3) during quinidine administration. Al-
though a reduction in skeletal muscle digoxin concentration
may account for the reduction in digoxin volume of distri-
bution seen after quinidine treatment (4), the magnitude of
the reduction was too small to be measured even with paired
comparisons and the ultrasensitive radionuclide techniques
used in this study.
The kidney/serum digoxin concentration ratio is not al-
tered at steady state during the quinidine-digoxin interac-
tion. In a previous study (17), we found that quinidine
administered to dogs for 24 hours did not produce a change
in serum digoxin concentration, but did result in a lower
ratio of kidney/serum digoxin concentration compared with
dogs treated with digoxin alone. In this earlier study, dogs
given digoxin and quinidine for 3 days had the same kid-
ney/serum digoxin concentration ratio as dogs given digoxin
alone. Similarly, in the present study, there was no differ-
ence in kidney/serum digoxin concentration ratio between
dogs treated with digoxin alone and dogs treated with di-
goxin and quinidine in combination until a new steady-state
serum digoxin concentration had been reached (an average
of 5.5 days). Although observations made before steady-
state serum drug concentrations have been reached during
the quinidine-digoxin interaction may provide useful infor-
mation about the interaction, such observations cannot be
extrapolated to the conditions at steady state.
Some of the neurologic effects of digoxin are attributed
to the action of digoxin in the brainstem medulla (17,18).
We have found in both this study and an earlier one (7) that
after quinidine treatment, the concentration of digoxin in
the brainstem medulla is less than would be expected from
the increase in serum digoxin concentration. How this find-
ing is related to digoxin effect needs further clarification.
Myocardial digoxin concentration and effect.
Myocardial digoxin concentration was higher in dogs given
quinidine, but there was no associated increase in digoxin
effect on either electrocardiographic intervals or myocardial
monovalent cation transport. Dogs treated with digoxin and
quinidine in combination had a significantly (p < 0.05)
longer RR interval than did dogs treated with digoxin alone,
which might be the result of the higher myocardial digoxin
143 ± 2
4.1 ± 0.5
7.46 ± 0.04
42 ± 13
85 ± 2
132 ± 8
83 ± 13
Digoxin and Quinidine
(n = 8)
DIGOXIN +QUINIDINE
SOC =2.1
Digoxin
(n = 9)
144 ± 2
4.2 ± 0.7
7.46 ± 0.05
36 ± 10
85 ± 7
132 ± 17
84 ± 12
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accounts for the difference in QT interval between the groups.
Using regression analysis, we could find no correlation be-
tween serum digoxin concentration, myocardial digoxin
concentration or serum quinidine concentration and rubid-
ium uptake or electrocardiographic intervals.
Blood pressure, serum electrolytes and blood gases.
Table 4 shows the average systolic and diastolic blood pres-
sures, the serum sodium and potassium levels and arterial
pH, partial pressures of oxygen and carbon dioxide for the
two experimental groups. There were no differences be-
tween groups in average values for any of these measurements.
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concentration. However, we did not find evidence of an
increase in digoxin effect on atrioventricular conduction
(that is, prolonged PR interval) or evidence of a quinidine
effect such as prolongation of QRS or QT intervals. Electro-
cardiographic intervals may have been influenced by di-
goxin, quinidine and the vagolytic effect of barbiturates and
are, therefore, difficult to interpret.
We have previously shown that myocardial monovalent
cation transport is a sensitive enough measure of digoxin
effect to distinguish between a group of dogs treated chron-
ically with digoxin until the average serum digoxin con-
centration is between I and 1.5 ng/ml and a group of dogs
treated with digoxin until the serum digoxin concentration
is between 2 and 3 ng/ml (13). In this study, we found that
the discrepancy between serum digoxin concentration and
myocardial digoxin effect cannot be accounted for by a
reduction in myocardial digoxin concentration, which in-
creases during quinidine administration and remains pro-
portional to the serum digoxin concentration. Kuschinsky
et al. (24) estimated that only 10% of digoxin in the myo-
cardium is bound to active receptor sites. Myocardial di-
goxin effect during quinidine administration is approxi-
mately 50% of that expected from the myocardial digoxin
concentration. If digoxin were displaced only from active
receptor sites, the observed discrepancy between myocardial
digoxin concentration and effect would require a displace-
ment of only 5% of the total myocardial digoxin concen-
tration (50% of the 10% bound to active sites). The tech-
niques that we have used to measure myocardial digoxin
concentration are the most accurate available. Using these
techniques, the interindividual variability in myocardial di-
goxin concentration is 10 to 15%, which could obscure a
5% average change in myocardial digoxin concentration.
Studies of digoxin binding to its specific receptor on the
membrane sodium, potassium-adenosine triphosphatase
during the quinidine-digoxin interaction will be necessary
to determine whether or not a reduction in binding of digoxin
to its active receptor site accounts for the failure of the effect
of digoxin to increase in proportion to the serum and myo-
cardial digoxin concentration during the quinidine-digoxin
interaction.
Although the finding that monovalent cation transport is
not inhibited to the extent predicted from the serum or
myocardial digoxin concentration during quinidine admin-
istration suggests that digoxin may have less than the pre-
dicted effect on myocardial contractility and cardiac ar-
rhythmias, this has not been conclusively shown. Not all
of the effects of digoxin are related to its inhibition of
myocardial monovalent cation transport (13,14). Maneuvers
such as C1 spinal cord transection alter the usual relation
between inhibition of monovalent cation transport and de-
velopment of ventricular tachycardia (17). It is possible that
quinidine also alters this relation. In addition, Somberg et
al. {l4) reported that quinidine does not change the relation
between serum digoxin concentration and inhibition of mon-
ovalent cation transport in Purkinje fibers and suggested that
digoxin-toxic arrhythmias might arise from Purkinje fibers
during quinidine administration.
Conclusions. When the serum digoxin concentration in-
creases during quinidine administration, the concentration
of digoxin in many tissues, including the myocardium, in-
creases proportionally. However, although the concentra-
tion of digoxin in the myocardium and other tissues increases
with the serum digoxin concentration during quinidine
administration, the effect of digoxin on monovalent cation
transport is less than expected from the serum or myocardial
digoxin concentration. The dissociation of serum digoxin
concentration from digoxin effect on myocardial mono-
valent cation transport that has been previously reported to
occur during the quinidine-digoxin interaction (13,14) can-
not be explained by a reduction in myocardial digoxin
concentration.
We thank Zena Toran for expert preparation of the figures.
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